TrianglePAXALISIB (NCT04906096)
PAXALISIB trial for Primary Central Nervous System Lymphoma (NCT04906096). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent or refractory primary central nervous system diffuse large B-cell lymphoma visible on MRI. Active systemic disease and previous PI3K or mTOR inhibitors exclude participation.
The idea: paxalisib blocks PI3K signaling involved in cancer-cell growth and survival. Patients take it by mouth daily in twenty-eight-day cycles for up to two years, provided disease does not progress and side effects remain acceptable. Researchers measure tumor response and safety.
This phase 2 study plans 25 patients. Lakshmi Nayak leads at Dana-Farber in Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.